摘要
目的:探讨胸腺肽联合化疗对晚期胃肠道肿瘤患者细胞免疫功能的影响。方法:将80例晚期胃肠道肿瘤患者随机分为化疗组和胸腺肽联合化疗组,化疗组采用常规化疗治疗,胸腺肽联合化疗组在化疗基础上加用胸腺肽。25例体检者作为健康对照组。分别于治疗前及2周化疗期结束后10天检测外周血T淋巴细胞亚群及Thl型细胞因子(IL-2)、Th2型细胞因子(IL-10)。结果:与健康对照组相比,晚期胃肠道肿瘤患者治疗前T淋巴细胞亚群(CD3+,CD4+和CD4+/CD8+比值)及IL-2明显下降,CD8+及IL-10升高(P<0.05)。治疗后两组患者CD3+,CD4+,CD4+/CD8+比值明显升高(P<0.05),胸腺肽联合化疗组变化更显著,与化疗组有显著差异(P<0.05)。胸腺肽联合化疗组患者IL-2下降(P<0.05),IL-10升高(P<0.05),化疗组IL-2,IL-10与化疗前相比没有统计学意义。胸腺肽联合化疗组有效率高于化疗组(P<0.05)。结论:晚期胃肠道肿瘤患者T淋巴细胞免疫功能低下,Th2类细胞因子呈优势表达。胸腺肽联合化疗可杀灭肿瘤细胞,减轻肿瘤负荷,改善患者的细胞免疫功能。
Objective：To study the influence of chemotherapy combined with thynlopetidum on cellular immunity of patients with gastrointestinal malignant tumor in the later stage. Methods：80 cases were divided into two groups：testing group （40 cases,with thymopetidum and chemotherapy） and control group （40 cases,with chemotherapy only）. 25 cases without malignant tumors were selected as normal group. The activity of T-lymphocyte subgroup and its cytokines as IL-2 （The） and IL-10 （Th2） in peripheral blood of each group were investigated before treatment and at the tenth day after treatment of two weeks. Results：Before treatment, T-lymphocyte subset （CD3^＋,CD4^＋ and the ratio of CD4^＋/CD8^＋） and IL-2 of patients with gatrointestinal malignant tumor were lower than those of normal group（P 〈 0.05）,while the values of CD8^＋ and IL-10 were higher obviously compared with normal group（P 〈 0.05）. After treated for two weeks, CD3^＋,CD4^＋ and the ratio of CD4^＋/CD8^＋ were higher than those of before treatment in two groups（P 〈 0.05）,and the changes in testing group were more obviously than those in control group （P 〈 0.05）. In testing group,IL-2 was lower and IL-10 was higher than before treatment（P 〈 0.05）,while there was no significant change after treatment in control group. The efficacy of testing group was higher than that of control group（P 〈 0.05）. Conclusions：The immunity of T-lymphocyte subgroup was suppressed in the patients with gastrointestinal malignant tumor and the expression of Th2 type cytokines was enhanced. The cellular immunity of patients was improved by killing the tumor cells and removing the immunosuppressive agent after the chemotherapy together with Thymopetidum.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2009年第11期1588-1590,共3页
Journal of Nanjing Medical University(Natural Sciences)
关键词
胸腺肽
胃肠道肿瘤
T淋巴细胞亚群
化疗
thymopetidum
gastroinstinal malignant tumor
T-lymphocyte subgroup
chemotherapy
